A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Solid Tumors And Lymphomas
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically- or cytologically-confirmed relapsed/refractory metastatic or locally-advanced solid tumor or lymphoma whose disease has progressed despite all appropriate curative or life-prolonging treatments, are intolerant to these therapies or have refused standard treatment. Note: Cohort enrollment may be limited to potentially immune-responsive tumor types meeting the above criterion during the first approximately 2 weeks of the enrollment period of each cohort due to their potential to respond to and activate TRQ15-01: o Non-small cell lung cancer o Melanoma o Clear cell cancer of the kidney o Head and neck squamous cell cancer o Urothelial cancer o Lymphoma o Sarcomas o Ovarian Cancer o Other tumors determined likely to be immunogenic based upon emerging data as discussed during escalation teleconferences 2) Patients with measurable disease (at least one measurable lesion, at least 1.0 cm in diameter) documented within 10 weeks of their projected C1D1 visit, as determined by RECIST v1.1 for patients with solid tumors; or Lugano classification; or if nodal, at least 1.5cm or greater in the short axis dimension for patients with lymphoma

You may not be eligible for this study if the following are true:

  • 1) Previously identified hypersensitivity to components of TRQ15-01 or excipients 2) Patients with T-cell lymphomas or small lymphocytic lymphoma 3) Active infection requiring systemic antibiotic therapy. 4) Patients receiving systemic treatment with any immunosuppressive medication.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.